Press releases
- AbCellera Reports Q1 2024 Business Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
- AbCellera to Present at Upcoming Investor Conferences in March
- AbCellera Reports Full Year 2023 Business Results
More ▼
Key statistics
As of last trade Abcellera Biologics Inc (8QQ:DUS) traded at 3.39, 0.74% above its 52-week low of 3.36, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.45 |
---|---|
High | 3.46 |
Low | 3.39 |
Bid | 3.39 |
Offer | 3.42 |
Previous close | 3.38 |
Average volume | 115.78 |
---|---|
Shares outstanding | 294.05m |
Free float | 211.77m |
P/E (TTM) | -- |
Market cap | 1.11bn USD |
EPS (TTM) | -0.5056 USD |
Data delayed at least 15 minutes, as of May 17 2024 15:31 BST.
More ▼